Mali operates under one of the world's most strained healthcare systems, with physician density measured at 0.14 doctors per 1,000 people according to World Health Organization data from 2018. The capital Bamako hosts approximately 60 percent of the country's qualified physicians and nearly all advanced diagnostic equipment. Outside Bamako, medical infrastructure diminishes sharply, with cities like Mopti, Sikasso, and Ségou offering basic clinical services but lacking consistent access to blood products, surgical anesthesia beyond ketamine, or imaging beyond plain radiography. In northern cities including Timbuktu, Gao, and Kidal, medical infrastructure has been further degraded by armed conflict since 2012, with many facilities operating without reliable electricity, running water, or consistent pharmaceutical supply chains. Travelers requiring specialized medical care beyond basic wound management or oral rehydration will need evacuation to Bamako at minimum, and for complex conditions to Dakar in Senegal or European facilities.
Yellow fever vaccination with a valid International Certificate of Vaccination is mandatory for all travelers arriving from countries with risk of yellow fever transmission and is recommended for all travelers over nine months of age by the Centers for Disease Control. Mali experiences endemic yellow fever transmission, with the last major documented outbreak occurring in 1987 in the Sikasso region, though surveillance capacity limitations mean actual incidence likely exceeds reported figures. The vaccine must be administered at least 10 days before entry and provides lifelong protection under current WHO guidelines as of 2016, though some countries still require certificates dated within 10 years. Travelers cannot obtain yellow fever vaccination upon arrival in Mali and will face rejection at entry points including Modibo Keita International Airport in Bamako without valid documentation.
Malaria transmission occurs year-round throughout Mali with peak intensity during the rainy season from June through October. Plasmodium falciparum accounts for approximately 85 percent of cases and exhibits documented resistance to chloroquine and sulfadoxine-pyrimethamine across all regions. The CDC recommends atovaquone-proguanil, doxycycline, or mefloquine as prophylaxis options, with selection dependent on individual contraindications and trip duration. Atovaquone-proguanil requires daily dosing starting one to two days before arrival and continuing seven days after departure. Doxycycline similarly requires daily administration but carries photosensitivity concerns in Mali's intense equatorial sun exposure, particularly in Saharan zones where UV index regularly exceeds 11. Mefloquine requires weekly dosing beginning two weeks before travel but carries neuropsychiatric contraindications that eliminate it for some travelers. Mali's malaria incidence exceeds 200 cases per 1,000 population in hyperendemic zones including the Inner Niger Delta and areas around Mopti. No prophylaxis regimen provides complete protection, and rapid diagnostic tests available in Bamako pharmacies lack the sensitivity of microscopy for detecting low-level parasitemia.
Routine vaccinations including measles-mumps-rubella require verification of two-dose completion for all adults born after 1957, as Mali experiences periodic measles outbreaks with the most recent significant transmission in 2018 affecting Bamako and Kayes regions. Polio vaccination records should document completion of childhood series plus a single adult booster, as Mali reported a case of circulating vaccine-derived poliovirus type 2 in August 2019 in Bamako. Tetanus-diphtheria requires boosting every 10 years, with pertussis component added if not received as an adolescent or adult. These diseases circulate in Mali at rates substantially higher than in industrialized nations due to vaccination coverage gaps, particularly in rural areas and among populations displaced by conflict in northern regions.
Hepatitis A vaccine is universally recommended for Mali travel regardless of itinerary or accommodation standard. Transmission occurs through contaminated food and water, with highest risk associated with items handled after cooking including salads, unpeeled fruits washed in local water, and ice. The vaccine requires two doses separated by six to 12 months for lifelong immunity, though a single dose administered at any point before travel provides adequate protection for trips up to one year. Hepatitis A seroprevalence in Mali exceeds 90 percent in adults over age 40, indicating near-universal exposure in the local population. Travelers eating exclusively at hotels or expatriate-standard restaurants in Bamako still face transmission risk from water used in washing produce and from ice made from municipal supplies that undergo inconsistent chlorination.
Hepatitis B vaccination follows a three-dose schedule at months zero, one, and six, though an accelerated schedule exists for last-minute travelers departing before completion. Mali's hepatitis B surface antigen prevalence stands at approximately 11 percent based on surveillance data from the 2010s, placing it in the high endemicity category. Transmission routes include medical and dental procedures with inadequately sterilized equipment, sexual contact, and traditional scarification or tattooing practices. Medical facilities outside Bamako rarely have reliable autoclaves or single-use equipment, and even in Bamako, standards vary dramatically between private clinics serving expatriates and public facilities. Travelers requiring dental work, injections, or any invasive procedure during extended stays face meaningful exposure risk. The vaccine series can be initiated at any point before travel, with partial protection developing after the first dose.
Typhoid fever circulates throughout Mali with year-round transmission intensifying during the rainy season when water supplies face increased fecal contamination. Two vaccine options exist: an oral live attenuated vaccine requiring four capsules on alternate days, with the final dose completed at least one week before potential exposure, and an injectable polysaccharide vaccine administered as a single dose at least two weeks before travel. The oral vaccine provides approximately 80 percent protection for five years but cannot be taken by immunocompromised individuals or anyone on antibiotics. The injectable vaccine offers approximately 70 percent protection for two years. Mali's water and sewage infrastructure remains minimal outside central Bamako, with most of the population relying on wells that frequently test positive for fecal coliform bacteria. Typhoid transmission risk exists even in upper-tier accommodations when municipal water is used for washing dishes, preparing uncooked foods, or making ice.
Rabies vaccination follows a three-dose pre-exposure schedule at days zero, seven, and 21 or 28. Mali has endemic canine rabies with an estimated 99 percent of human cases resulting from dog bites, based on regional data from similar West African countries where surveillance exists. Domestic dogs in both urban and rural areas frequently roam without supervision, and many show visible signs of illness. Bats in Mali carry rabies variants, and the country's fruit bat populations occasionally come into contact with humans in agricultural areas. Pre-exposure vaccination does not eliminate the need for post-exposure treatment but reduces it from five doses plus immunoglobulin to two doses without immunoglobulin. Rabies immunoglobulin remains unavailable in Mali as of current reporting, and travelers exposed without pre-vaccination require evacuation to access this component of post-exposure prophylaxis, which must be initiated within days of exposure for effectiveness. Pre-exposure vaccination makes sense for travelers spending more than two weeks in Mali, anyone staying in rural areas, or those whose activities might involve animal contact including visiting markets where live animals are sold.
Meningococcal meningitis follows a seasonal pattern in Mali, which sits within the African meningitis belt extending from Senegal to Ethiopia. The dry season from December through May brings harmattan winds from the Sahara, and dust, low humidity below 20 percent, and upper respiratory tract damage that facilitates meningococcal invasion. Mali experiences epidemic waves, with the most recent significant outbreak in 2012 reporting over 1,000 cases concentrated in Bamako, Sikasso, and Ségou. The quadrivalent conjugate vaccine covering serogroups A, C, W, and Y addresses the strains circulating in West Africa. Vaccination requirements become mandatory during pilgrimages and mass gatherings, though Mali does not enforce routine entry requirements for most travelers. Symptoms including severe headache, fever, and neck stiffness progress rapidly, and case fatality rates in Mali exceed 10 percent even with treatment due to delays in accessing appropriate antibiotics. Ceftriaxone represents the treatment standard, but rural health posts often lack this medication or the capacity to administer intravenous antibiotics.
Japanese encephalitis, tick-borne encephalitis, and altitude illness medications carry no relevance for Mali travel. The country's maximum elevation of 1,155 meters at Mount Hombori does not trigger altitude considerations. Japanese encephalitis does not occur in Africa, and tick-borne encephalitis remains confined to Europe and Asia.